The Myeloma Beacon

Independent, up-to-date news and information for the multiple myeloma community.
Home page Deutsche Artikel Artículos Españoles

Forums

Discussion about multiple myeloma treatments, stem cell transplants, clinical trials, alternative medicines, supplements, and their benefits and side effects.

MTI-101 as potential new multiple myeloma treatment

by Ellen Harris on Fri Nov 09, 2018 3:51 pm

Hi all,

I hope this is a possible new path to a cure!

Emmons, MF, et al, "MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma," Scientific Reports, June 2, 2017 (full text of article)

Abstract:

The emergence of drug resistance continues to be a major hurdle towards improving patient out­comes for the treatment of Multiple Myeloma. MTI-101 is a first-in-class peptido­mimetic that binds a CD44/ITGA4 contain­ing complex and triggers necrotic cell death in multiple myeloma cell lines. In this report, we show that acquisition of resistance to MTI-101 correlates with changes in expression of genes predicted to attenuate Ca2+ flux. Consistent with the acquired resistant geno­type, MTI-101 treatment induces a rapid and robust increase in intra­cellular Ca2+ levels in the parental cells; a finding that was attenuated in the acquired drug resistant cell line. Mechanistically, we show that pharma­cological inhibition of store operated channels or reduction in the expression of a component of the store operated Ca2+ channel, TRPC1 blocks MTI-101 induced cell death. Importantly, MTI-101 is more potent in specimens obtained from relapsed myeloma patients, suggesting that relapse may occur at a cost for increased sensitivity to Ca2+ overload mediated cell death. Finally, we demonstrate that MTI-101 is synergistic when combined with bortezomib, using both myeloma cell lines and primary myeloma patient specimens. Together, these data continue to support the develop­ment of this novel class of compounds for the treat­ment of relapsed myeloma.

Also:

Gebhard, AW, et al., "Mti-101 (cyclized HYD1) Binds to CD44 and Induces Necrotic Cell Death in Multiple Myeloma," Blood, ASH 2012 Abstract 4022 (full text of abstract)

Ellen Harris

Re: MTI-101 as potential new multiple myeloma treatment

by Mike F on Tue Nov 13, 2018 11:57 am

Here's an article on one of the people involved in this research. It's pretty recent and sounds like they're getting ready to move into animal studies. Hope it works!

https://www.wvnews.com/news/wvnews/wvu-grad-student-researching-treatment-for-aggressive-blood-cancer/article_9045675f-28d9-5b8b-bd96-d6acef818dd4.html

Mike F
Name: Mike F
Who do you know with myeloma?: Me
When were you/they diagnosed?: May 18, 2012
Age at diagnosis: 53


Return to Treatments & Side Effects